{"id":923425,"date":"2026-01-04T10:03:05","date_gmt":"2026-01-04T15:03:05","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/sinovac-receives-nasdaq-notification-regarding-late-filing-of-2025-half-year-report\/"},"modified":"2026-01-04T10:03:05","modified_gmt":"2026-01-04T15:03:05","slug":"sinovac-receives-nasdaq-notification-regarding-late-filing-of-2025-half-year-report","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/sinovac-receives-nasdaq-notification-regarding-late-filing-of-2025-half-year-report\/","title":{"rendered":"Sinovac Receives Nasdaq Notification Regarding Late Filing of 2025 Half-Year Report"},"content":{"rendered":"<p>        <!--body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p><b>Sinovac Receives Nasdaq Notification Regarding Late Filing of 2025 Half-Year Report<\/b><\/p>\n<p>BEIJING&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nSinovac Biotech Ltd. (NASDAQ: SVA) (\u201c<b>SINOVAC<\/b>\u201d or the \u201c<b>Company<\/b>\u201d), a leading provider of biopharmaceutical products in China, today announced that it has received a notification letter dated January 2, 2026 (the \u201c<b>Notification Letter<\/b>\u201d) from Nasdaq Listing Qualifications (\u201c<b>Nasdaq<\/b>\u201d), stating that the Company was not in compliance with Nasdaq\u2019s Listing Rule 5250(c)(2) since the Company did not timely file a Form 6-K containing an interim balance sheet and income statement as of the end of its second quarter of year 2025.<\/p>\n<p>\nAs previously disclosed, the Company received a delisting determination letter (the \u201c<b>Staff Determination<\/b>\u201d) from Nasdaq in November 2025. The Company requested a hearing before the Nasdaq Hearings Panel to appeal the Staff Determination on November 19, 2025. Nasdaq has informed the Company that the Nasdaq Hearings Panel will also consider the matter addressed in the Notification Letter at a hearing scheduled for January 8, 2026 at which the Company has been invited to present its views regarding this matter.<\/p>\n<p>\nThe Company is evaluating the Notification Letter and intends to present its plan and views to the Nasdaq Hearings Panel at the scheduled hearing with the objective of maintaining its Nasdaq listing.<\/p>\n<p><b>Safe Harbor Statement<\/b><\/p>\n<p>\nThis announcement contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;aim,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;is\/are likely to&#8221; or other similar expressions. Such statements are based upon current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company&#8217;s or Board&#8217;s control, which may cause actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company&#8217;s filings with the U.S. Securities and Exchange Commission. The Company and Board do not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.<\/p>\n<p><b>About SINOVAC<\/b><\/p>\n<p>\nSinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission of &#8220;supply vaccines to eliminate human diseases&#8221;, the company specializes in the research, development, manufacturing and commercialization of vaccines and related biological products that protect against human infectious diseases.<\/p>\n<p>\nThe company&#8217;s diversified portfolio includes vaccines for influenza, viral hepatitis, varicella, Hand-Foot-Mouth disease (HFMD), poliomyelitis, pneumococcal disease, etc., of which 3 vaccines have been prequalified by WHO, including inactivated hepatitis A vaccine Healive<sup>\u00ae<\/sup>, Sabin-strain inactivated polio vaccine (sIPV), and varicella vaccine.<\/p>\n<p>\nSINOVAC has a leading edge in developing vaccines to combat infectious disease outbreaks and was among the first to initiate R&amp;D during major public health emergencies, including SARS, H5N1, H1N1, and COVID-19. The company developed the world&#8217;s first inactivated SARS vaccine (Phase I completed), China&#8217;s first H5N1 influenza vaccine (Panflu<sup>\u00ae<\/sup>), the world&#8217;s first H1N1 influenza vaccine (Panflu.1<sup>\u00ae<\/sup>), and CoronaVac<sup>\u00ae<\/sup>, the most widely used inactivated COVID-19 vaccine globally.<\/p>\n<p>\nBeyond its marketed portfolio, the company is advancing a robust pipeline that includes combination vaccines, recombinant protein vaccines and next-generation platforms such as mRNA technologies and antibodies.<\/p>\n<p>\nWith a long-standing commitment to innovation and global health, SINOVAC is expanding its global footprint by strengthening partnerships with research institutions, international organizations, and local partners. Through broader market presence, technological cooperation, and localized production, the company aims to accelerate vaccine development and supply, enhance regional access to high-quality products, and better address unmet medical needs while improving preparedness for future pandemics.<\/p>\n<p>\nFor more information, please see the Company\u2019s website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sinovac.com&amp;esheet=54387829&amp;newsitemid=20260104600593&amp;lan=en-US&amp;anchor=www.sinovac.com&amp;index=1&amp;md5=791760ae13567a670c476367f0b3a8d2\">www.sinovac.com<\/a>.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260104600593r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260104600593\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260104600593\/en\/<\/a><\/span><\/p>\n<p>\nInvestor and Media Contact<br \/>\n<br \/>Sinovac Biotech Ltd.<br \/>\n<br \/>Email: <a rel=\"nofollow\" href=\"mailto:ir@sinovac.com\">ir@sinovac.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> China Asia Pacific<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Infectious Diseases Biotechnology Pharmaceutical Health<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\" \/>\n","protected":false},"excerpt":{"rendered":"<p>Sinovac Receives Nasdaq Notification Regarding Late Filing of 2025 Half-Year Report BEIJING&#8211;(BUSINESS WIRE)&#8211; Sinovac Biotech Ltd. (NASDAQ: SVA) (\u201cSINOVAC\u201d or the \u201cCompany\u201d), a leading provider of biopharmaceutical products in China, today announced that it has received a notification letter dated January 2, 2026 (the \u201cNotification Letter\u201d) from Nasdaq Listing Qualifications (\u201cNasdaq\u201d), stating that the Company was not in compliance with Nasdaq\u2019s Listing Rule 5250(c)(2) since the Company did not timely file a Form 6-K containing an interim balance sheet and income statement as of the end of its second quarter of year 2025. As previously disclosed, the Company received a delisting determination letter (the \u201cStaff Determination\u201d) from Nasdaq in November 2025. The Company requested a hearing before the Nasdaq Hearings &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sinovac-receives-nasdaq-notification-regarding-late-filing-of-2025-half-year-report\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Sinovac Receives Nasdaq Notification Regarding Late Filing of 2025 Half-Year Report&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-923425","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Sinovac Receives Nasdaq Notification Regarding Late Filing of 2025 Half-Year Report - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sinovac-receives-nasdaq-notification-regarding-late-filing-of-2025-half-year-report\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sinovac Receives Nasdaq Notification Regarding Late Filing of 2025 Half-Year Report - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Sinovac Receives Nasdaq Notification Regarding Late Filing of 2025 Half-Year Report BEIJING&#8211;(BUSINESS WIRE)&#8211; Sinovac Biotech Ltd. (NASDAQ: SVA) (\u201cSINOVAC\u201d or the \u201cCompany\u201d), a leading provider of biopharmaceutical products in China, today announced that it has received a notification letter dated January 2, 2026 (the \u201cNotification Letter\u201d) from Nasdaq Listing Qualifications (\u201cNasdaq\u201d), stating that the Company was not in compliance with Nasdaq\u2019s Listing Rule 5250(c)(2) since the Company did not timely file a Form 6-K containing an interim balance sheet and income statement as of the end of its second quarter of year 2025. As previously disclosed, the Company received a delisting determination letter (the \u201cStaff Determination\u201d) from Nasdaq in November 2025. The Company requested a hearing before the Nasdaq Hearings &hellip; Continue reading &quot;Sinovac Receives Nasdaq Notification Regarding Late Filing of 2025 Half-Year Report&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/sinovac-receives-nasdaq-notification-regarding-late-filing-of-2025-half-year-report\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-04T15:03:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260104600593r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sinovac-receives-nasdaq-notification-regarding-late-filing-of-2025-half-year-report\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sinovac-receives-nasdaq-notification-regarding-late-filing-of-2025-half-year-report\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Sinovac Receives Nasdaq Notification Regarding Late Filing of 2025 Half-Year Report\",\"datePublished\":\"2026-01-04T15:03:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sinovac-receives-nasdaq-notification-regarding-late-filing-of-2025-half-year-report\\\/\"},\"wordCount\":682,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sinovac-receives-nasdaq-notification-regarding-late-filing-of-2025-half-year-report\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260104600593r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sinovac-receives-nasdaq-notification-regarding-late-filing-of-2025-half-year-report\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sinovac-receives-nasdaq-notification-regarding-late-filing-of-2025-half-year-report\\\/\",\"name\":\"Sinovac Receives Nasdaq Notification Regarding Late Filing of 2025 Half-Year Report - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sinovac-receives-nasdaq-notification-regarding-late-filing-of-2025-half-year-report\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sinovac-receives-nasdaq-notification-regarding-late-filing-of-2025-half-year-report\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260104600593r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-01-04T15:03:05+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sinovac-receives-nasdaq-notification-regarding-late-filing-of-2025-half-year-report\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sinovac-receives-nasdaq-notification-regarding-late-filing-of-2025-half-year-report\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sinovac-receives-nasdaq-notification-regarding-late-filing-of-2025-half-year-report\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260104600593r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260104600593r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sinovac-receives-nasdaq-notification-regarding-late-filing-of-2025-half-year-report\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sinovac Receives Nasdaq Notification Regarding Late Filing of 2025 Half-Year Report\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sinovac Receives Nasdaq Notification Regarding Late Filing of 2025 Half-Year Report - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/sinovac-receives-nasdaq-notification-regarding-late-filing-of-2025-half-year-report\/","og_locale":"en_US","og_type":"article","og_title":"Sinovac Receives Nasdaq Notification Regarding Late Filing of 2025 Half-Year Report - Market Newsdesk","og_description":"Sinovac Receives Nasdaq Notification Regarding Late Filing of 2025 Half-Year Report BEIJING&#8211;(BUSINESS WIRE)&#8211; Sinovac Biotech Ltd. (NASDAQ: SVA) (\u201cSINOVAC\u201d or the \u201cCompany\u201d), a leading provider of biopharmaceutical products in China, today announced that it has received a notification letter dated January 2, 2026 (the \u201cNotification Letter\u201d) from Nasdaq Listing Qualifications (\u201cNasdaq\u201d), stating that the Company was not in compliance with Nasdaq\u2019s Listing Rule 5250(c)(2) since the Company did not timely file a Form 6-K containing an interim balance sheet and income statement as of the end of its second quarter of year 2025. As previously disclosed, the Company received a delisting determination letter (the \u201cStaff Determination\u201d) from Nasdaq in November 2025. The Company requested a hearing before the Nasdaq Hearings &hellip; Continue reading \"Sinovac Receives Nasdaq Notification Regarding Late Filing of 2025 Half-Year Report\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/sinovac-receives-nasdaq-notification-regarding-late-filing-of-2025-half-year-report\/","og_site_name":"Market Newsdesk","article_published_time":"2026-01-04T15:03:05+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260104600593r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sinovac-receives-nasdaq-notification-regarding-late-filing-of-2025-half-year-report\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sinovac-receives-nasdaq-notification-regarding-late-filing-of-2025-half-year-report\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Sinovac Receives Nasdaq Notification Regarding Late Filing of 2025 Half-Year Report","datePublished":"2026-01-04T15:03:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sinovac-receives-nasdaq-notification-regarding-late-filing-of-2025-half-year-report\/"},"wordCount":682,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sinovac-receives-nasdaq-notification-regarding-late-filing-of-2025-half-year-report\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260104600593r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sinovac-receives-nasdaq-notification-regarding-late-filing-of-2025-half-year-report\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/sinovac-receives-nasdaq-notification-regarding-late-filing-of-2025-half-year-report\/","name":"Sinovac Receives Nasdaq Notification Regarding Late Filing of 2025 Half-Year Report - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sinovac-receives-nasdaq-notification-regarding-late-filing-of-2025-half-year-report\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sinovac-receives-nasdaq-notification-regarding-late-filing-of-2025-half-year-report\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260104600593r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-01-04T15:03:05+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sinovac-receives-nasdaq-notification-regarding-late-filing-of-2025-half-year-report\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/sinovac-receives-nasdaq-notification-regarding-late-filing-of-2025-half-year-report\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sinovac-receives-nasdaq-notification-regarding-late-filing-of-2025-half-year-report\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260104600593r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260104600593r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sinovac-receives-nasdaq-notification-regarding-late-filing-of-2025-half-year-report\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Sinovac Receives Nasdaq Notification Regarding Late Filing of 2025 Half-Year Report"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/923425","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=923425"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/923425\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=923425"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=923425"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=923425"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}